Fig. 1 · Structure

Documents & Downloads

Amonafide (AS1413)

Cat. No. A10071 CAS 69408-81-7

Topoisomerase inhibitor

Amonafide is a DNA intercalator and topoisomerase II inhibitor for the treatment of neoplastic diseases, one of Antitumor agent.

In Stock

Publications for Amonafide

1 publication citing this product

  1. Veronica Rendo, .et al. , Nat Commun, 2020, 11: 1308 PMID: 32161261

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Amonafide stimulates sequence-selective DNA cleavage mediated by purified mammalian topoisomerase II. In a murine-enzyme assay, its pBR322 cleavage pattern differed from those produced by other Topo II-active agents. This supports a Topo II-poisoning mechanism; it does not establish a biochemical IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Topo II

Cellular Effect

Cell Line Activity Value Description Reference
A 172 GI50 > 25 μM Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay [PMID: 28710962]
A 172 GI50 > 25 μM Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay [PMID: 28710962]
A 172 IC50 23.81 μM Cytotoxicity against human A 172 cells assessed as cell viability measured after 96 hrs by XTT assay [PMID: 34507011]
A2780 IC50 11.66 μM Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay [PMID: 36894107]
A-375 IC50 14.7 μM Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay [PMID: 17331719]
A-375 IC50 7.51 μM Cytotoxicity against human A375 cells by MTT assay [PMID: 19643513]
A549 IC50 1.1 μM Cytotoxicity against human A549 cells by SRB assay [PMID: 23353750]
A549 IC50 1.1 μM Cytotoxicity against human A549 cells by sulforhodamine B dye staining method [PMID: 17331719]
A549 IC50 1.59 μM Cytotoxicity against human A549 cells after 48 hrs by MTT assay 10.1039/C5MD00543D
A549 IC50 1100 nM Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B dye assay [PMID: 17707644]
A549 IC50 1100 nM Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. [PMID: 10956214]
A549 IC50 1100 nM Cytotoxic concentration against human A549 lung cancer cell line determined by sulforhodamine B dye-staining method [PMID: 15876532]
A549 IC50 13 μM Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay [PMID: 24370011]
A549 IC50 13 μM Cytotoxicity against human A549 cells by SRB assay [PMID: 19643513]
A549 IC50 13 μM Growth inhibition of human A549 cells by SRB assay [PMID: 17532640]
A549 IC50 2 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 29342415]
A549 IC50 23.46 μM Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 33965862]
A549 IC50 3.2 μM Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay [PMID: 23770449]
A549 IC50 3.8 μM Antiproliferative activity against A549 cells after 72 hrs by MTT assay [PMID: 17658777]
A549 IC50 7.76 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 30774856]

20 records · Scroll to view more

Amonafide (AS1413) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Amonafide (AS1413) from 3 published references. In vitro models include human AGS gastric carcinoma cells. In vivo models include male nude (nu/nu) mice bearing subcutaneous HepG2 xenografts.

Amonafide (AS1413) In Vitro Studies

In AGS gastric carcinoma cells, 5 μM amonafide increased the high-DNA-content/G2-M fraction after 24 h (P < .05 versus vehicle), which the authors interpreted as G2 arrest. [2]

Amonafide acetylation depends on NAT2 phenotype. In engineered RKO and DLD-1 colorectal cancer cells exposed to 10 μM amonafide for 30 min, rapid NAT2 clones showed higher acetylation velocity than slow NAT2 clones. This metabolic result should be distinguished from cytotoxic potency. [3]

Sequence-selective topoisomerase II-mediated DNA cleavage

Biochemical assay · Purified murine P388-derived topoisomerase II and an end-labeled pBR322 DNA fragment [1]

Amonafide produced a cleavage pattern distinct from other Topo II-active comparators in a purified-enzyme assay. The experiment supports stimulation of enzyme-mediated DNA cleavage; it does not measure a binding affinity or an inhibitory IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Topoisomerase II-mediated pBR322 DNA cleavageCleavage pattern Sequence-selective cleavage[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 10 and 50 μM (Figure 2 amonafide lanes)
Exposure duration
30 min at 37°C
Method
Cell-free DNA cleavage assay; DNA-only and enzyme-only lanes present
Reported limits
Drug stock solvent and replicate count not specified in the reviewed locations.
Methods and source locations

Compound reported in the paper: Amonafide; Compound label in the paper: amonafide

Parent amonafide literature result; salt/lot equivalence is not established.

p. 224 Materials and DNA cleavage reaction; p. 225 Figure 2 and Results: High site selectivity of amonafide stimulation of topoisomerase II DNA cleavage

Topoisomerase II-mediated pBR322 DNA cleavage: Denaturing polyacrylamide gel analysis — p. 224 Materials and DNA cleavage reaction; p. 225 Figure 2 and Results: High site selectivity of amonafide stimulation of topoisomerase II DNA cleavage

AGS cell-cycle response

Cell-based study · Human AGS gastric carcinoma cells [2]

After 24 h, amonafide at 5 μM significantly increased the high-DNA-content/G2-M fraction relative to vehicle. The authors interpret this as G2 arrest. The DNA-content assay alone does not distinguish G2 from mitosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Increase in high-DNA-content/G2-M fraction relative to vehicleStatistical significance P < .05 at 5 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
1.25, 2.5 and 5 μM displayed in Figure 1C; significant effect reported at 5 μM
Exposure duration
24 h
Method
Treatment followed by DNA-content flow cytometry
Vehicle
1% DMSO (Figure 1 legend)
Reported limits
No numeric phase percentages extracted from the plot; no dose recommendation inferred.
Methods and source locations

Compound reported in the paper: Amonafide; Compound label in the paper: AMN

Parent amonafide literature result; salt/lot equivalence is not established.

Figure 1C and legend; Methods: MTT Assay (DNA-content assay paragraph); Results: AMN, AN, and MEAN Share Similar In Vitro Growth Inhibition and Apoptotic Properties

Increase in high-DNA-content/G2-M fraction relative to vehicle: DNA-content flow cytometry; one-way ANOVA with Dunnett test. Figure legend specifies SD from three or more independent experiments. — Figure 1C and legend; Methods: MTT Assay (DNA-content assay paragraph); Results: AMN, AN, and MEAN Share Similar In Vitro Growth Inhibition and Apoptotic Properties

NAT2-dependent amonafide acetylation

Cell-based study · Human RKO and DLD-1 colorectal cancer cells expressing rapid NAT2*13A or slow NAT2*6A; parental and vector controls [3]

Rapid NAT2 clones acetylated amonafide faster than slow NAT2 clones in a cell-based LC-MS/MS assay. The original figure also tests procainamide as a separate substrate; it is not an amonafide combination treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Acetylation velocity in rapid versus slow NAT2 clonesRelative acetylation velocity ≥8-fold higher in rapid NAT2 clones (text groups amonafide and procainamide results); RKO P < 0.0001; DLD-1 P < 0.05[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
30 min before quenching
Method
Cell-based acetylation assay with LC-MS/MS detection of amonafide and N-acetyl-amonafide
Reported limits
Stock solvent, salt and lot/catalog number not specified in this assay section; absolute velocity values were not estimated from bars.
Methods and source locations

Compound reported in the paper: Amonafide; Compound label in the paper: amonafide

Parent amonafide literature result; salt/lot equivalence is not established.

Results: Discovery of compounds selectively toxic to slow NAT2 cells (Sec4, paragraph beginning We reasoned); Figure 2a–d and legend; Methods: Quantification of NAT2 catalytic activity in cell lysates (Sec13)

Acetylation velocity in rapid versus slow NAT2 clones: LC-MS/MS; Figure 2c,d shows means of two independent experiments. P values are from Results text; no amonafide-specific statistical test is identified there. — Results: Discovery of compounds selectively toxic to slow NAT2 cells (Sec4, paragraph beginning We reasoned); Figure 2a–d and legend; Methods: Quantification of NAT2 catalytic activity in cell lysates (Sec13)

Amonafide (AS1413) In Vivo Studies

In a HepG2 xenograft study, intraperitoneal amonafide once daily for 14 days reduced endpoint tumor weight, with reported growth inhibition of 47.8% at 50 μmol/kg and 76.7% at 100 μmol/kg (both P < .01 versus vehicle). Each group began with 10 mice; final group sizes were 10 and 9, respectively. These findings do not establish a tolerated clinical dose. [2]

HepG2 xenograft endpoint tumor weight

Animal study · Male nude (nu/nu) mice bearing subcutaneous HepG2 xenografts [2]

Daily amonafide reduced endpoint tumor weight at both tested doses. Final group sizes were 10/10 at 50 μmol/kg and 9/10 at 100 μmol/kg, compared with 10/10 for vehicle. This is an efficacy experiment with tolerability limitations, not a PK study.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Resected tumor weight after treatmentTumor weight Vehicle: 2.185 ± 0.242 g; 50 μmol/kg: 1.141 ± 0.216 g; 100 μmol/kg: 0.509 ± 0.199 g[2]
Tumor growth inhibition relative to vehicleGrowth inhibition 50 μmol/kg: 47.8%; 100 μmol/kg: 76.7%; both P < .01[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
14 days, beginning 2 weeks after xenograft implantation
Vehicle
20% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle
0 μmol/kg
Vehicle group; initial n = 10 per groupTumor weight 2.185 ± 0.242 g; final n = 10/10[2]
Amonafide 50 μmol/kgVehicle group; initial n = 10 per groupTumor weight 1.141 ± 0.216 g; final n = 10/10; growth inhibition 47.8%; P < .01 versus vehicle (unpaired t-test)[2]
Amonafide 100 μmol/kgVehicle group; initial n = 10 per groupTumor weight 0.509 ± 0.199 g; final n = 9/10; growth inhibition 76.7%; P < .01 versus vehicle (unpaired t-test)[2]
Vehicle
Model: Male nude (nu/nu) mice with subcutaneous HepG2 xenografts
Reported limits: Table 1 does not define the ± term. Cause of the missing animal in the 100 μmol/kg group is not specified in Table 1.
Amonafide 50 μmol/kg
Model: Male nude (nu/nu) mice with subcutaneous HepG2 xenografts
Reported limits: Table 1 does not define the ± term. Cause of the missing animal in the 100 μmol/kg group is not specified in Table 1.
Amonafide 100 μmol/kg
Model: Male nude (nu/nu) mice with subcutaneous HepG2 xenografts
Reported limits: Table 1 does not define the ± term. Cause of the missing animal in the 100 μmol/kg group is not specified in Table 1.
Methods and source locations

Compound reported in the paper: Amonafide; Compound label in the paper: AMN

Parent amonafide literature result; salt/lot equivalence is not established.

Table 1 and legend; Results: Numonafides Are Efficacious in a Hepatoma Xenograft Model, but MEAN Is Better Tolerated than AMN and AN; Methods: Mice and xenografts

Resected tumor weight after treatment: Endpoint resected-tumor weighing; ± definition not given in Table 1. — Table 1 and legend; Results: Numonafides Are Efficacious in a Hepatoma Xenograft Model, but MEAN Is Better Tolerated than AMN and AN; Methods: Mice and xenografts

Tumor growth inhibition relative to vehicle: As reported in Table 1; unpaired t-test versus vehicle. Each group began with 10 mice. — Table 1 and legend; Results: Numonafides Are Efficacious in a Hepatoma Xenograft Model, but MEAN Is Better Tolerated than AMN and AN; Methods: Mice and xenografts

Vehicle · Table 1 and legend; Results: Numonafides Are Efficacious in a Hepatoma Xenograft Model, but MEAN Is Better Tolerated than AMN and AN; Methods: Mice and xenografts

Amonafide 50 μmol/kg · Table 1 and legend; Results: Numonafides Are Efficacious in a Hepatoma Xenograft Model, but MEAN Is Better Tolerated than AMN and AN; Methods: Mice and xenografts

Amonafide 100 μmol/kg · Table 1 and legend; Results: Numonafides Are Efficacious in a Hepatoma Xenograft Model, but MEAN Is Better Tolerated than AMN and AN; Methods: Mice and xenografts

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 69408-81-7
Applications Topoisomerase inhibitor
Formula C16H17N3O2
Molecular Weight 283.3
Synonyms Xanafide; Quinamed; AS1413
SMILES
CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 51 mg/mL (179.99 mM)
Water Insoluble
Ethanol 4 mg/mL (14.11 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Amonafide (AS1413) Research References

  1. [1] De Isabella P, Zunino F, Capranico G. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage. Nucleic acids research (1995). PMID: 7862525 DOI: 10.1093/nar/23.2.223 Source material
  2. [2] Liu Y, Norton JT, Witschi MA, et al. Methoxyethylamino-numonafide is an efficacious and minimally toxic amonafide derivative in murine models of human cancer. Neoplasia (New York, N.Y.) (2011). PMID: 21532886 DOI: 10.1593/neo.101738 Source material
  3. [3] Rendo V, Stoimenov I, Mateus A, et al. Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nature communications (2020). PMID: 32161261 DOI: 10.1038/s41467-020-15111-4 Source material

Publications

1 publication citing this product

  1. Veronica Rendo, .et al. , Nat Commun, 2020, 11: 1308 PMID: 32161261

Added to your cart

View Cart Checkout
Loading...